Taking aim at Alzheimer's disease through the mammalian target of rapamycin

References

• Maiese K, Chong ZZ, Hou J, Shang YC. New strategies for Alzheimer's disease and cognitive impairment. Oxid Med Cell Longev. 2009;2: 279–89.
   Google Scholar
• Filley CM, Rollins YD, Anderson CA, Arciniegas DB, Howard KL, Murrell JR, et al. The genetics of very early onset Alzheimer disease. Cogn Behav Neurol. 2007;20:149–56.
   PubMed Web of Science ®Google Scholar
• Agis-Torres A, Solhuber M, Fernandez M, Sanchez-Montero JM. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer's disease. Curr Neuropharmacol. 2014;12:2–36.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol. 2005;75:207–46.
   PubMed Web of Science ®Google Scholar
• Maiese K, Chong ZZ, Wang S, Shang YC. Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade. Int J Mol Sci. 2013;13:13830–66.
   Google Scholar
• Mizuno S, Iijima R, Ogishima S, Kikuchi M, Matsuoka Y, Ghosh S, et al. AlzPathway: a comprehensive map of signaling pathways of Alzheimer's disease. BMC Syst Biol. 2012;6:52.
   PubMed Web of Science ®Google Scholar
• Maiese K, Chong ZZ, Shang YC, Wang S. mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med. 2013;19:51–60.
   PubMed Web of Science ®Google Scholar
• Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253:905–9.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159–68.
   PubMed Web of Science ®Google Scholar
• Wang L, Lawrence JC Jr, Sturgill TW, Harris TE. Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. J Biol Chem. 2009;284:14693–7.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Q, Wen Q, Zheng Y, Philip L, Jiang H, et al. Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signal. 2012;24:17–24.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006;11:859–71.
   PubMed Web of Science ®Google Scholar
• Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell. 2003;11:895–904.
   PubMed Web of Science ®Google Scholar
• Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson RB. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors. 2007;25:209–26.
   PubMed Web of Science ®Google Scholar
• Lenz G, Avruch J. Glutamatergic regulation of the p70S6 kinase in primary mouse neurons. J Biol Chem. 2005;280:38121–4.
   Google Scholar
• Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, et al. Hypothalamic mTOR signaling regulates food intake. Science. 2006;312:927–30.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Wang S, Maiese K. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol. 2012;99:128–48.
   PubMed Web of Science ®Google Scholar
• Shang YC, Chong ZZ, Wang S, Maiese K. Tuberous sclerosis protein 2 (TSC2) modulates CCN4 cytoprotection during apoptotic amyloid toxicity in microglia. Curr Neurovasc Res. 2013;10:29–38.
   PubMed Web of Science ®Google Scholar
• DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008;22:239–51.
   PubMed Web of Science ®Google Scholar
• Cai Z, Li B, Li K, Zhao B. Down-regulation of amyloid-beta through AMPK activation by inhibitors of GSK-3beta in SH-SY5Y and SH-SY5Y-AbetaPP695 cells. J Alzheimers Dis. 2012;29:89–98.
   PubMed Web of Science ®Google Scholar
• Salminen A, Kaarniranta K, Haapasalo A, Soininen H, Hiltunen M. AMP-activated protein kinase: a potential player in Alzheimer's disease. J Neurochem. 2011;118:460–74.
   PubMed Web of Science ®Google Scholar
• Paiva MA, Rutter-Locher Z, Goncalves LM, Providencia LA, Davidson SM, Yellon DM, et al. Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2011;300:H2123–34.
   Google Scholar
• Cheng PW, Ho WY, Su YT, Lu PJ, Chen BZ, Cheng WH, et al. Resveratrol decrease fructose-induced oxidative stress mediated by NADPH oxidase via an AMPK-dependent mechanism. Br J Pharmacol. 2014;171:2739–50.
   PubMed Web of Science ®Google Scholar
• Jessen N, Koh HJ, Folmes CD, Wagg C, Fujii N, Lofgren B, et al. Ablation of LKB1 in the heart leads to energy deprivation and impaired cardiac function. Biochim Biophys Acta. 2010;1802:593–600.
   Google Scholar
• Lai CS, Tsai ML, Badmaev V, Jimenez M, Ho CT, Pan MH. Xanthigen suppresses preadipocyte differentiation and adipogenesis through down-regulation of PPARgamma and C/EBPs and modulation of SIRT-1, AMPK, and FoxO pathways. J Agric Food Chem. 2012;60: 1094–101.
   PubMed Web of Science ®Google Scholar
• Aragno M, Mastrocola R, Ghe C, Arnoletti E, Bassino E, Alloatti G, et al. Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms. Cardiovasc Diabetol. 2012; 11:129.
   Google Scholar
• Kang S, Chemaly ER, Hajjar RJ, Lebeche D. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. J Biol Chem. 2011;286: 18465–73.
   Google Scholar
• Pearce LR, Sommer EM, Sakamoto K, Wullschleger S, Alessi DR. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem J. 2011;436:169–79.
   PubMed Web of Science ®Google Scholar
• Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008;28:4104–15.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Wang S, Maiese K. SIRT1: new avenues of discovery for disorders of oxidative stress. Expert Opin Ther Targets. 2012;16:167–78.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Li F, Maiese K. Attempted cell cycle induction in post-mitotic neurons occurs in early and late apoptotic programs through Rb, E2F1, and caspase 3. Curr Neurovasc Res. 2006;3:25–39.
   PubMedGoogle Scholar
• Folch J, Junyent F, Verdaguer E, Auladell C, Pizarro JG, Beas-Zarate C, et al. Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death. Neurotox Res. 2012;22:195–207.
   PubMed Web of Science ®Google Scholar
• Turunc Bayrakdar E, Uyanikgil Y, Kanit L, Koylu E, Yalcin A. Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Abeta(1-42)-induced rat model of Alzheimer's disease. Free Radic Res. 2014;48:146–58.
   PubMed Web of Science ®Google Scholar
• Wang CM, Liu MY, Wang F, Wei MJ, Wang S, Wu CF, et al. Anti- amnesic effect of pseudoginsenoside-F11 in two mouse models of Alzheimer's disease. Pharmacol Biochem Behav. 2013;106:57–67.
   Google Scholar
• Maiese K, Chong ZZ, Shang YC, Wang S. Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Ther Targets. 2012;16:1203–14.
   PubMed Web of Science ®Google Scholar
• Broe M, Shepherd CE, Milward EA, Halliday GM. Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol. 2001;101:616–24.
   PubMedGoogle Scholar
• Louneva N, Cohen JW, Han LY, Talbot K, Wilson RS, Bennett DA, et al. Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. Am J Pathol. 2008;173:1488–95.
   PubMed Web of Science ®Google Scholar
• Biswas SC, Shi Y, Vonsattel JP, Leung CL, Troy CM, Greene LA. Bim is elevated in Alzheimer's disease neurons and is required for beta-amyloid-induced neuronal apoptosis. J Neurosci. 2007;27:893–900.
   PubMed Web of Science ®Google Scholar
• Lourhmati A, Buniatian GH, Paul C, Verleysdonk S, Buecheler R, Buadze M, et al. Age-dependent astroglial vulnerability to hypoxia and glutamate: the role for erythropoietin. PLoS One. 2013;8:e77182.
   Google Scholar
• Jiang T, Yu JT, Zhu XC, Tan MS, Wang HF, Cao L, et al. Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer's disease. Pharmacol Res. 2014;81C:54–63.
   Google Scholar
• Chen L, Xu B, Liu L, Luo Y, Yin J, Zhou H, et al. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Lab Invest. 2010;90:762–73.
   PubMed Web of Science ®Google Scholar
• Chen TJ, Wang DC, Chen SS. Amyloid-beta interrupts the PI3K-Akt-mTOR signaling pathway that could be involved in brain-derived neurotrophic factor-induced Arc expression in rat cortical neurons. J Neurosci Res. 2009;87:2297–307.
   PubMed Web of Science ®Google Scholar
• Wang GB, Ni YL, Zhou XP, Zhang WF. The AKT/mTOR pathway mediates neuronal protective effects of erythropoietin in sepsis. Mol Cell Biochem. 2014;385:125–32.
   PubMed Web of Science ®Google Scholar
• Shang YC, Chong ZZ, Wang S, Maiese K. Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Curr Neurovasc Res. 2011;8:270–85.
   PubMed Web of Science ®Google Scholar
• Shang YC, Chong ZZ, Wang S, Maiese K. Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY). 2012;4:187–201.
   PubMedGoogle Scholar
• Zare Mehrjerdi F, Aboutaleb N, Habibey R, Ajami M, Soleimani M, Arabian M, et al. Increased phosphorylation of mTOR is involved in remote ischemic preconditioning of hippocampus in mice. Brain Res. 2013;1526:94–101.
   PubMed Web of Science ®Google Scholar
• Shi GD, OuYang YP, Shi JG, Liu Y, Yuan W, Jia LS. PTEN deletion prevents ischemic brain injury by activating the mTOR signaling pathway. Biochem Biophys Res Commun. 2011;404:941–5.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol. 2007;150:839–50.
   PubMed Web of Science ®Google Scholar
• Shang YC, Chong ZZ, Hou J, Maiese K. Wnt1, FoxO3a, and NF-kappaB oversee microglial integrity and activation during oxidant stress. Cell Signal. 2010;22:1317–29.
   PubMedGoogle Scholar
• Uranga RM, Katz S, Salvador GA. Enhanced phosphatidylinositol 3-kinase (PI3K)/Akt signaling has pleiotropic targets in hippocampal neurons exposed to iron-induced oxidative stress. J Biol Chem. 2013;288:19773–84.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Li F, Maiese K. Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signal. 2007;19: 1150–62.
   PubMed Web of Science ®Google Scholar
• Zara S, De Colli M, Rapino M, Pacella S, Nasuti C, Sozio P, et al. Ibuprofen and lipoic acid conjugate neuroprotective activity is mediated by Ngb/Akt intracellular signaling pathway in Alzheimer's disease rat model. Gerontology. 2013;59:250–60.
   Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002;106:2973–9.
   PubMed Web of Science ®Google Scholar
• Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293:90–5.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang S, Shang YC, Chong ZZ, Maiese K. Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovasc Res. 2011; 8:220–35.
   PubMed Web of Science ®Google Scholar
• Sanghera KP, Mathalone N, Baigi R, Panov E, Wang D, Zhao X, et al. The PI3K/Akt/mTOR pathway mediates retinal progenitor cell survival under hypoxic and superoxide stress. Mol Cell Neurosci. 2011;47:145–53.
   PubMed Web of Science ®Google Scholar
• Wu S, Mikhailov A, Kallo-Hosein H, Hara K, Yonezawa K, Avruch J. Characterization of ubiquilin 1, an mTOR-interacting protein. Biochim Biophys Acta. 2002;1542:41–56.
   PubMed Web of Science ®Google Scholar
• Mizukami K, Abrahamson EE, Mi Z, Ishikawa M, Watanabe K, Kinoshita S, et al. Immunohistochemical analysis of ubiquilin-1 in the human hippocampus: association with neurofibrillary tangle pathology. Neuropathology. 2014;34:11–18.
   Google Scholar
• Maiese K, Chong ZZ, Shang YC. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med. 2008;14:219–27.
   PubMed Web of Science ®Google Scholar
• Hong YK, Lee S, Park SH, Lee JH, Han SY, Kim ST, et al. Inhibition of JNK/dFOXO pathway and caspases rescues neurological impairments in Drosophila Alzheimer's disease model. Biochem Biophys Res Commun. 2012;419:49–53.
   PubMed Web of Science ®Google Scholar
• Shang YC, Chong ZZ, Hou J, Maiese K. The forkhead transcription factor FoxO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res. 2009;6:20–31.
   PubMedGoogle Scholar
• Chamorro ME, Wenker SD, Vota DM, Vittori DC, Nesse AB. Signaling pathways of cell proliferation are involved in the differential effect of erythropoietin and its carbamylated derivative. Biochim Biophys Acta. 2013;1833:1960–8.
   Google Scholar
• Chong ZZ, Hou J, Shang YC, Wang S, Maiese K. EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3beta, and beta-catenin to foster vascular integrity during experimental diabetes. Curr Neurovasc Res. 2011;8:103–20.
   PubMed Web of Science ®Google Scholar
• Melnik BC, Zouboulis CC. Potential role of FoxO1 and mTORC1 in the pathogenesis of Western diet-induced acne. Exp Dermatol. 2013;22:311–15.
   PubMedGoogle Scholar
• Shang YC, Chong ZZ, Wang S, Maiese K. WNT1 inducible signaling pathway protein 1 (WISP1) Targets PRAS40 to govern beta-amyloid apoptotic injury of microglia. Curr Neurovasc Res. 2012;9:239–49.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Wang S, Maiese K. PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection. PLoS One. 2012;7:e45456.
   PubMed Web of Science ®Google Scholar
• Xiong X, Xie R, Zhang H, Gu L, Xie W, Cheng M, et al. PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways. Neurobiol Dis. 2014;66:43–52.
   PubMed Web of Science ®Google Scholar
• Das F, Dey N, Venkatesan B, Kasinath BS, Ghosh-Choudhury N, Choudhury GG. High glucose upregulation of early-onset Parkinson's disease protein DJ-1 integrates the PRAS40/TORC1 axis to mesangial cell hypertrophy. Cell Signal. 2011;23:1311–19.
   PubMed Web of Science ®Google Scholar
• Hao J, Li F, Liu W, Liu Q, Liu S, Li H, et al. Phosphorylation of PRAS40-Thr246 involves in renal lipid accumulation of diabetes. J Cell Physiol. 2014;229:1069–77.
   PubMed Web of Science ®Google Scholar
• Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, Perault-Pochat MC, Gil R, et al. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J Neurochem. 2005;94:215–25.
   PubMed Web of Science ®Google Scholar
• Huang H, Huang F, Huang JP. Transplantation of bone marrow derived endothelial progenitor cells overexpressing Delta-like-4 enhances functional neovascularization in ischemic myocardium. Mol Med Rep. 2013;8:1556–62.
   Google Scholar
• Koh PO. Ferulic acid attenuates focal cerebral ischemia-induced decreases in p70S6 kinase and S6 phosphorylation. Neurosci Lett. 2013;555:7–11.
   PubMed Web of Science ®Google Scholar
• Treins C, Alliouachene S, Hassouna R, Xie Y, Birnbaum MJ, Pende M. The combined deletion of S6K1 and Akt2 deteriorates glycaemic control in high fat diet. Mol Cell Biol. 2012;32:4001–11.
   PubMed Web of Science ®Google Scholar
• Yamada E, Singh R. Mapping autophagy on to your metabolic radar. Diabetes. 2012;61:272–80.
   PubMed Web of Science ®Google Scholar
• Balduini W, Carloni S, Buonocore G. Autophagy in hypoxia-ischemia induced brain injury. J Matern Fetal Neonatal Med. 2012;25(Suppl 1):30–4.
   Google Scholar
• Kulbe JR, Mulcahy Levy JM, Coultrap SJ, Thorburn A, Bayern KU. Excitotoxic glutamate insults block autophagic flux in hippocampal neurons. Brain Res. 2014;1542:12–19.
   Google Scholar
• Chen A, Xiong LJ, Tong Y, Mao M. Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the PI3K/Akt/mTOR pathway. Mol Med Rep. 2013;8:1011–16.
   PubMed Web of Science ®Google Scholar
• Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One. 2010;5:e9313.
   PubMed Web of Science ®Google Scholar
• Hyrskyluoto A, Reijonen S, Kivinen J, Lindholm D, Korhonen L. GADD34 mediates cytoprotective autophagy in mutant huntingtin expressing cells via the mTOR pathway. Exp Cell Res. 2012;318:33–42.
   PubMed Web of Science ®Google Scholar
• Jeong JK, Moon MH, Bae BC, Lee YJ, Seol JW, Kang HS, et al. Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity. Neurosci Res. 2012;73:99–105.
   PubMed Web of Science ®Google Scholar
• Sekiguchi A, Kanno H, Ozawa H, Yamaya S, Itoi E. Rapamycin promotes autophagy and reduces neural tissue damage and locomotor impairment after spinal cord injury in mice. J Neurotrauma. 2012;29:946–56.
   Google Scholar
• Choi KC, Kim SH, Ha JY, Kim ST, Son JH. A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death. J Neurochem. 2010;112:366–76.
   PubMed Web of Science ®Google Scholar
• Bains M, Zaegel V, Mize-Berge J, Heidenreich KA. IGF-I stimulates Rab7-RILP interaction during neuronal autophagy. Neurosci Lett. 2011;488:112–17.
   Google Scholar
• Yin B, Liang H, Chen Y, Chu K, Huang L, Fang L, et al. EGB1212 post-treatment ameliorates hippocampal CA1 neuronal death and memory impairment induced by transient global cerebral ischemia/reperfusion. Am J Chin Med. 2013;41:1329–41.
   PubMed Web of Science ®Google Scholar
• Walker CL, Walker MJ, Liu NK, Risberg EC, Gao X, Chen J, et al. Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injury. PLoS One. 2012;7:e30012.
   PubMed Web of Science ®Google Scholar
• Francois A, Terro F, Janet T, Bilan AR, Paccalin M, Page G. Involvement of interleukin-1beta in the autophagic process of microglia: relevance to Alzheimer's disease. J Neuroinflammation. 2013;10:151.
   PubMed Web of Science ®Google Scholar
• Viola G, Bortolozzi R, Hamel E, Moro S, Brun P, Castagliuolo I, et al. MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochem Pharmacol. 2012;83:16–26.
   PubMed Web of Science ®Google Scholar
• Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A. 2010;107:12469–74.
   PubMed Web of Science ®Google Scholar
• Wang S, Chong ZZ, Shang YC, Maiese K. WISP1 (CCN4) autoregulates its expression and nuclear trafficking of beta-catenin during oxidant stress with limited effects upon neuronal autophagy. Curr Neurovasc Res. 2012;9:89–99.
   Web of Science ®Google Scholar
• Qinli Z, Meiqing L, Xia J, Li X, Weili G, Xiuliang J, et al. Necrostatin-1 inhibits the degeneration of neural cells induced by aluminum exposure. Restor Neurol Neurosci. 2013;31:543–55.
   PubMed Web of Science ®Google Scholar
• Dillon CP, Weinlich R, Rodriguez DA, Cripps JG, Quarato G, Gurung P, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell. 2014;157:1189–202.
   PubMed Web of Science ®Google Scholar
• Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest. 2010;120:1310–23.
   PubMed Web of Science ®Google Scholar
• Werneck MB, Hottz E, Bozza PT, Viola JP. Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway. Cell Cycle. 2012;11:3997–4008.
   PubMed Web of Science ®Google Scholar
• Liu X, Chhipa RR, Nakano I, Dasgupta B. The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent. Mol Cancer Ther. 2014;13:596–605.
   PubMed Web of Science ®Google Scholar
• Li L, Xu B, Zhu Y, Chen L, Sokabe M. DHEA prevents Abeta25–35-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling. Neuropharmacology. 2010;59:323–33.
   PubMed Web of Science ®Google Scholar
• Gong R, Park CS, Abbassi NR, Tang SJ. Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons. J Biol Chem. 2006;281:18802–15.
   PubMed Web of Science ®Google Scholar
• Parsons RG, Gafford GM, Helmstetter FJ. Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons. J Neurosci. 2006;26:12977–83.
   PubMed Web of Science ®Google Scholar
• Blundell J, Kouser M, Powell CM. Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation. Neurobiol Learn Mem. 2008;90:28–35.
   PubMed Web of Science ®Google Scholar
• Paccalin M, Pain-Barc S, Pluchon C, Paul C, Besson MN, Carret- Rebillat AS, et al. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;22:320–6.
   PubMed Web of Science ®Google Scholar
• Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, et al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One. 2010;5.
   Google Scholar
• Chano T, Okabe H, Hulette CM. RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases. Brain Res. 2007;1168:97–105.
   Google Scholar
• Shahani N, Pryor W, Swarnkar S, Kholodilov N, Thinakaran G, Burke RE, et al. Rheb GTPase regulates beta-secretase levels and amyloid beta generation. J Biol Chem. 2014;289:5799–808.
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem. 2005;93:105–17.
   PubMed Web of Science ®Google Scholar
• Tang Z, Bereczki E, Zhang H, Wang S, Li C, Ji X, et al. Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease. J Biol Chem. 2013;288: 15556–70.
   PubMed Web of Science ®Google Scholar
• An WL, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, et al. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol. 2003;163:591–607.
   PubMed Web of Science ®Google Scholar
• Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One. 2010;5:e9979.
   PubMed Web of Science ®Google Scholar
• Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, et al. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell. 2013;12:370–80.
   PubMed Web of Science ®Google Scholar
• Liu Y, Su Y, Wang J, Sun S, Wang T, Qiao X, et al. Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase. Neurochem Int. 2013;62:458–67.
   Google Scholar
• Zhu Z, Yan J, Jiang W, Yao XG, Chen J, Chen L, et al. Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both beta-amyloid production and clearance. J Neurosci. 2013;33:13138–49.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Li F, Maiese K. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med. 2007;19:263–72.
   PubMedGoogle Scholar
• Talos DM, Sun H, Zhou X, Fitzgerald EC, Jackson MC, Klein PM, et al. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS One. 2012;7:e35885.
   PubMed Web of Science ®Google Scholar
• Tang Z, Baykal AT, Gao H, Quezada HC, Zhang H, Bereczki E, et al. mTor Is a signaling hub in cell survival: a mass-spectrometry-based proteomics investigation. J Proteome Res. 2014 Apr 14. [Epub ahead of print].
   Google Scholar
• Barrett D, Brown VI, Grupp SA, Teachey DT. Targeting the PI3K/AKT/mTOR Signaling axis in children with hematologic malignancies. Paediatr Drugs. 2012;14:299–316.
   PubMed Web of Science ®Google Scholar
• Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009;94:4107–12.
   PubMed Web of Science ®Google Scholar
• Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011;71:3246–56.
   PubMed Web of Science ®Google Scholar
• Maiese K. Therapeutic targets for cancer: current concepts with PI 3-K, Akt, & mTOR. Indian J Med Res. 2013;137:243–6.
   Google Scholar
• Wang S, Wu J, Nie SD, Bereczki E, Pei JJ. Dysregulated mTOR- dependent signaling in neurodegeneration or carcinogenesis: implication for Alzheimer's disease and brain tumors. J Alzheimers Dis. 2013;37:495–505.
   Google Scholar
• Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363: 1801–11.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo- controlled, phase 3 study. Lancet. 2011;378:2005–12.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Moavero R. mTOR inhibitors as a new therapeutic option for epilepsy. Expert review of neurotherapeutics. 2013;13:627–38.
   PubMed Web of Science ®Google Scholar
• Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci. 2009;29:6964–72.
   PubMed Web of Science ®Google Scholar
• Guo W, Qian L, Zhang J, Zhang W, Morrison A, Hayes P, et al. Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling. J Neurosci Res. 2011;89:1723–36.
   PubMed Web of Science ®Google Scholar